Health
Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight – BioSpace
Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic…
Series of preclinical studies demonstrate the therapeutic potential of PAT-DX1, a first-in-class, synthetically lethal DNA-binding antibody in primary brain cancers and brain metastases.MELBOURNE–(BUSINESS WIRE)– Patrys Limited (ASX:PAB), a therapeutic…
Continue Reading
-
General16 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
Business22 hours ago3 of the best ASX ETFs for beginners to buy with $1,000
-
Business20 hours agoWhy this ASX 200 tech stock could rise 20%
-
Business23 hours ago$10,000 invested in Woodside shares 4 years ago is now worth…